Terremoto Biosciences Raises $108 Million in Series C Funding
Terremoto Biosciences, a company leveraging covalent chemistry to enhance small molecule medicines, announced on April 15, 2026, that it has secured $108 million in its Series C funding round. The investment will support the company's mission to develop superior therapeutic solutions.
Investors and Strategic Backing
The Series C round saw participation from a range of prominent investors. The roster includes BeOne Medicines, Cormorant Asset Management, Deep Track Capital, Novo Holdings, OrbiMed, Osage University Partners, RA Capital Management, and Third Rock Ventures. While no lead investor was specified, the collective backing from these firms underscores strong confidence in Terremoto's potential.
Leadership and Vision
Peter Thompson, the Chairman and Co-Founder of Terremoto Biosciences, continues to guide the company with a vision of transforming the landscape of small molecule therapies. His leadership has been pivotal in steering the company towards innovative approaches in drug development.
Allocation of Funds
The newly acquired funds are expected to be directed towards advancing the company's research and development efforts. This includes expanding their pipeline of small molecule medicines and potentially increasing their operational capabilities to enhance therapeutic outcomes. Specific details regarding the allocation were not disclosed, but the focus remains on leveraging their unique approach to covalent chemistry.
Conclusion
The successful closure of the Series C funding round marks a significant milestone for Terremoto Biosciences. With substantial backing from industry-leading investors, the company is well-positioned to continue its work in developing next-generation therapies that promise improved efficacy and patient outcomes.